Awards for “TEVA PHARMACEUTICALS USA, INC.”
25 awards on this page · sorted by amount · page 17
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| SPE2DP20F5512 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-06-17 | 2020-06-23 | 325412 | 8507472346!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5511 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-06-17 | 2020-06-23 | 325412 | 8507472345!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5011 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-05-21 | 2020-05-28 | 325412 | 8507395378!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5005 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-05-21 | 2020-05-28 | 325412 | 8507395370!ADENOVIRUS TYPE 4 A |
| SPE2DP20F3410 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-03-13 | 2020-03-24 | 325412 | 8507242537!ADENOVIRUS TYPE 4 A |
| SPE2DP20F3409 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-03-13 | 2020-03-24 | 325412 | 8507242536!ADENOVIRUS TYPE 4 A |
| SPE2DP20F3405 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-03-13 | 2020-03-24 | 325412 | 8507242531!ADENOVIRUS TYPE 4 A |
| SPE2DP20F2434 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $271.49K | 2020-02-07 | 2020-02-11 | 325412 | 8507153558!ADENOVIRUS TYPE 4 A |
| A079 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $267.04K | 2008-09-26 | 2008-09-29 | 325411 | 4508751779!AMOXICILL |
| V761C80024 | TEVA PHARMACEUTICALS USA, INC. | Department of Veterans Affairs | $254.46K | 2007-01-03 | 2007-12-06 | 325412 | DRUGS AND BIOLOGICALS FOR CMOP OCT 07//FY 08 |
| V760A80007 | TEVA PHARMACEUTICALS USA, INC. | Department of Veterans Affairs | $197.5K | 2007-11-05 | 2007-11-09 | 325412 | SIMVASTATIN 40MG TABS, 1000 CT |
| SPE2DP26F5465 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $171.76K | 2026-05-11 | 2026-05-19 | 325412 | 8512097232!ADENOVIRUS TYPE 4 A |
| SPE2DP26F4632 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $171.76K | 2026-04-15 | 2026-04-29 | 325412 | 8512041922!ADENOVIRUS TYPE 4 A |
| SPE2DP26F0987 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-12-01 | 2025-12-09 | 325412 | 8511784172!ADENOVIRUS TYPE 4 A |
| SPE2DP26F0986 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-12-01 | 2025-12-09 | 325412 | 8511784170!ADENOVIRUS TYPE 4 A |
| SPE2DP26F0981 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-12-01 | 2025-12-09 | 325412 | 8511784069!ADENOVIRUS TYPE 4 A |
| SPE2DP25F109X | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-09-08 | 2025-09-23 | 325412 | 8511624237!ADENOVIRUS TYPE 4 A |
| SPE2DP25F8219 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-06-16 | 2025-06-24 | 325412 | 8511446733!ADENOVIRUS TYPE 4 A |
| SPE2DP25F8218 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-06-16 | 2025-06-24 | 325412 | 8511446730!ADENOVIRUS TYPE 4 A |
| SPE2DP25F6741 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-05-12 | 2025-05-20 | 325412 | 8511369474!ADENOVIRUS TYPE 4 A |
| SPE2DP25F5528 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-04-07 | 2025-04-29 | 325412 | 8511296304!ADENOVIRUS TYPE 4 A |
| SPE2DP25F4438 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-03-06 | 2025-03-25 | 325412 | 8511229455!ADENOVIRUS TYPE 4 A |
| SPE2DP25F4437 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-03-06 | 2025-03-25 | 325412 | 8511229453!ADENOVIRUS TYPE 4 A |
| SPE2DP25F4436 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-03-06 | 2025-03-25 | 325412 | 8511229452!ADENOVIRUS TYPE 4 A |
| SPE2DP25F2793 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $165.16K | 2025-01-28 | 2025-02-04 | 325412 | 8511148053!ADENOVIRUS TYPE 4 A |